• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

GELDANAMYCIN Drug Record

  • Summary
  • Interactions
  • Claims
  • GELDANAMYCIN chembl:CHEMBL278315 Antineoplastic

    Alternate Names:

    GELDANAMYCIN
    NSC-122750
    chemidplus:30562-34-6
    drugbank:02424
    chembl:CHEMBL278315
    pubchem.compound:5288382

    Drug Info:

    (0 More Sources)

    Publications:

    Zagzag et al., 2003, Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion., J. Cell. Physiol.
    Zhao H et al., 2011, Identification and initial SAR of silybin: an Hsp90 inhibitor., Bioorg Med Chem Lett
    Degterev A et al., 2008, Identification of RIP1 kinase as a specific cellular target of necrostatins., Nat Chem Biol
    Hadden MK et al., 2007, Derrubone, an inhibitor of the Hsp90 protein folding machinery., J Nat Prod
    Li Z et al., 2014, Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors., Eur J Med Chem
    Matts RL et al., 2011, A systematic protocol for the characterization of Hsp90 modulators., Bioorg Med Chem
    Kusuma BR et al., 2011, Targeting the heat shock protein 90 dimer with dimeric inhibitors., J Med Chem
    Gunaherath GM et al., 2013, Synthesis and biological evaluation of novobiocin analogues as potential heat shock protein 90 inhibitors., Bioorg Med Chem
    Shaaban KA et al., 2013, Herbimycins D-F, ansamycin analogues from Streptomyces sp. RM-7-15., J Nat Prod
    Hall JA et al., 2015, Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery., J Nat Prod
    Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
    Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
    Schnaider et al., 1998, The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes., Life Sci.
    Berman et al., 2000, The Protein Data Bank., Nucleic Acids Res.
    Gavenonis J et al., 2014, Potential C-terminal-domain inhibitors of heat shock protein 90 derived from a C-terminal peptide helix., Bioorg Med Chem
    Chen CY et al., 2014, The antitumor agent PBT-1 directly targets HSP90 and hnRNP A2/B1 and inhibits lung adenocarcinoma growth and metastasis., J Med Chem
    Li Z et al., 2014, Design, synthesis and biological evaluation of 17-arylmethylamine-17-demethoxygeldanamycin derivatives as potent Hsp90 inhibitors., Eur J Med Chem
    Davenport J et al., 2011, Gambogic acid, a natural product inhibitor of Hsp90., J Nat Prod
    Edwards et al., 1995, Evidence for a dithiol-activated signaling pathway in natural killer cell avidity regulation of leukocyte function antigen-1: structural requirements and relationship to phorbol ester- and CD16-triggered pathways., Blood
    Nganga et al., 2000, Control of pancreatic bile-salt-dependent-lipase secretion by the glucose-regulated protein of 94 kDa (Grp94)., Biochem. J.
    Zhang et al., 2006, HSP90 protects apoptotic cleavage of vimentin in geldanamycin-induced apoptosis., Mol. Cell. Biochem.
    Yun et al., 2005, Differential effects of Hsp90 inhibition on protein kinases regulating signal transduction pathways required for myoblast differentiation., Exp. Cell Res.
    Luparello et al., 2003, PTHrP [67-86] regulates the expression of stress proteins in breast cancer cells inducing modifications in urokinase-plasminogen activator and MMP-1 expression., J. Cell. Sci.
    Puyo S et al., 2008, Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro., Mol Diagn Ther
    George et al., 2004, Cotreatment with 17-allylamino-demethoxygeldanamycin and FLT-3 kinase inhibitor PKC412 is highly effective against human acute myelogenous leukemia cells with mutant FLT-3., Cancer Res.
    George et al., 2005, Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3., Blood
  • GELDANAMYCIN   CDC37

    Interaction Score: 4.42

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21486005


    Sources:
    DTC

  • GELDANAMYCIN   VIM

    Interaction Score: 2.94

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    16328963


    Sources:
    NCI

  • GELDANAMYCIN   CEL

    Interaction Score: 2.21

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    11104697


    Sources:
    NCI

  • GELDANAMYCIN   HSP90AB1

    Interaction Score: 1.67

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    10592235 17016423 17139284 21273068 18408713 24984936 24428777 18020309 25277067 25105924 21861487 23859777 25756299


    Sources:
    DTC

  • GELDANAMYCIN   CD28

    Interaction Score: 1.47

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    9747895


    Sources:
    NCI

  • GELDANAMYCIN   MYOD1

    Interaction Score: 0.98

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15922741


    Sources:
    NCI

  • GELDANAMYCIN   FCGR3B

    Interaction Score: 0.46

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7662976


    Sources:
    NCI

  • GELDANAMYCIN   HSP90AA1

    Interaction Score: 0.39

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    21273068 18408713 18020309 25277067 21129982 21861487 23859777 23947794 25756299 17016423 17139284


    Sources:
    DTC

  • GELDANAMYCIN   FCGR3A

    Interaction Score: 0.37

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    7662976


    Sources:
    NCI

  • GELDANAMYCIN   PLAU

    Interaction Score: 0.34

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12724357


    Sources:
    NCI

  • GELDANAMYCIN   FLT3

    Interaction Score: 0.16

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15150124 15514006


    Sources:
    NCI

  • GELDANAMYCIN   HIF1A

    Interaction Score: 0.06

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    12811834


    Sources:
    NCI

  • GELDANAMYCIN   EGFR

    Interaction Score: 0.05

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    18652519


    Sources:
    PharmGKB

  • GELDANAMYCIN   ATAD5

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • NCI: GELDANAMYCIN

    • Version: 14-September-2017

    Alternate Names:
    C1112 NCI drug code

    Drug Info:

    Publications:
    Zagzag et al., 2003, Geldanamycin inhibits migration of glioma cells in vitro: a potential role for hypoxia-inducible factor (HIF-1alpha) in glioma cell invasion., J. Cell. Physiol.
    Edwards et al., 1995, Evidence for a dithiol-activated signaling pathway in natural killer cell avidity regulation of leukocyte function antigen-1: structural requirements and relationship to phorbol ester- and CD16-triggered pathways., Blood
    Schnaider et al., 1998, The Hsp90-specific inhibitor, geldanamycin, blocks CD28-mediated activation of human T lymphocytes., Life Sci.

  • DTC: GELDANAMYCIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL278315 ChEMBL Drug ID

    Drug Info:

    Publications:
    Hall JA et al., 2015, Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery., J Nat Prod
    Li Z et al., 2014, Discovery of diamine-linked 17-aroylamido-17-demethoxygeldanamycins as potent Hsp90 inhibitors., Eur J Med Chem
    Matts RL et al., 2011, A systematic protocol for the characterization of Hsp90 modulators., Bioorg Med Chem

  • PharmGKB: geldanamycin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Puyo S et al., 2008, Impact of EGFR gene polymorphisms on anticancer drug cytotoxicity in vitro., Mol Diagn Ther

  • ChemblDrugs: chembl:CHEMBL278315

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21